| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Tianze Yu, Yi Chen, Jiani Lu, Luyun Gong, Yuechen Mao, Xinya Liu, Yiying Zhou, Lei Guo, Xiang Wu, Junfang Zhang, Chuang Wang, Haowei Shen, Wenhua Zhou, Disen Mei, Wei Cu. Chronic multiple mild stress induces sustained adverse psychological states in rats. Neuroreport. vol 33. issue 15. 2022-09-20. PMID:36126265. |
moreover, cmms treatment leads to decreased production of serotonin and increased expression of corticotropin-releasing factor receptor 1, adrenocorticotropic hormone, and glucocorticoid in the brain, which were prevented by paroxetine and sertraline, two clinical-used antidepressants. |
2022-09-20 |
2023-08-14 |
human |
| Lucas Krawczyk, Shubham Semwal, Jalal Soubhye, Salma Lemri Ouadriri, Martin Prévost, Pierre Van Antwerpen, Goedele Roos, Julie Bouckaer. Native glycosylation and binding of the antidepressant paroxetine in a low-resolution crystal structure of human myeloperoxidase. Acta crystallographica. Section D, Structural biology. vol 78. issue Pt 9. 2022-09-01. PMID:36048150. |
the crystal structure also contains bound paroxetine, a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of mpo, in the presence of thiocyanate, a physiological substrate of mpo. |
2022-09-01 |
2023-08-14 |
human |
| Tyler T Henderson, Janet L Taylor, Jacob R Thorstensen, Murray G Tucker, Justin J Kavanag. Enhanced availability of serotonin limits muscle activation during high-intensity, but not low-intensity, fatiguing contractions. Journal of neurophysiology. 2022-08-24. PMID:36001790. |
in both experiments, the selective serotonin reuptake inhibitor (20 mg paroxetine), or a placebo, was administered in a two-way crossover-design. |
2022-08-24 |
2023-08-14 |
Not clear |
| Ani Gasparyan, Daniela Navarro, Francisco Navarrete, Jorge Manzanare. Pharmacological strategies for post-traumatic stress disorder (PTSD): From animal to clinical studies. Neuropharmacology. 2022-08-16. PMID:35973598. |
only sertraline and paroxetine, two selective serotonin reuptake inhibitors, are approved by different international agencies to treat ptsd. |
2022-08-16 |
2023-08-14 |
Not clear |
| Mudan Cai, Hee Ra Park, Eun Jin Yan. Nutraceutical Interventions for Post-Traumatic Stress Disorder in Animal Models: A Focus on the Hypothalamic-Pituitary-Adrenal Axis. Pharmaceuticals (Basel, Switzerland). vol 15. issue 7. 2022-07-27. PMID:35890196. |
the selective serotonin reuptake inhibitors (ssris), sertraline and paroxetine, are the only drugs that have been approved by the united states food and drug administration for the treatment of ptsd. |
2022-07-27 |
2023-08-14 |
Not clear |
| Allison Doyle Brackley, Nathaniel A Jesk. Paroxetine increases delta opioid responsiveness in sensory neurons. eNeuro. 2022-07-26. PMID:35882549. |
here, we report that paroxetine, a selective serotonin reuptake inhibitor and potent grk2 inhibitor (thal et al., 2012), reduces chronic grk2 association with membrane dor, thereby enhancing peripheral dor-mediated analgesic competence in the absence of inflammation. |
2022-07-26 |
2023-08-14 |
Not clear |
| Martina Tallarico, Maria Pisano, Antonio Leo, Emilio Russo, Rita Citraro, Giovambattista De Sarr. Antidepressants drugs for seizures and epilepsy: Where do we stand? Current neuropharmacology. 2022-06-28. PMID:35761500. |
newer ads, such as selective serotonin reuptake inhibitors (srri) or serotonin-noradrenaline reuptake inhibitors (snri), particularly sertraline, citalopram, mirtazapine, reboxetine, paroxetine, fluoxetine, escitalopram, fluvoxamine, venlafaxine, duloxetine may lead to improvements in epilepsy severity instead the use of older tricyclic antidepressant (tcas) can increase the occurrence of seizures. |
2022-06-28 |
2023-08-14 |
Not clear |
| Thu-Lan T Luong, Chelsea N Powers, Brian J Reinhardt, Peter J Wein. Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine. Current research in pharmacology and drug discovery. vol 3. 2022-06-27. PMID:35756846. |
pre-clinical drug-drug interactions (ddis) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (ssris): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine. |
2022-06-27 |
2023-08-14 |
Not clear |
| Kelly E Dunham, B Jill Vento. SSRI antidepressants differentially modulate serotonin reuptake and release in Drosophila. Journal of neurochemistry. 2022-06-23. PMID:35736504. |
we applied various doses (0.1 - 100 μm) of fluoxetine (prozac), escitalopram (lexapro), citalopram (celexa), and paroxetine (paxil), to ventral nerve cord (vnc) tissue and measured optogenetically-stimulated serotonin release with fast-scan cyclic voltammetry (fscv). |
2022-06-23 |
2023-08-14 |
drosophila_melanogaster |
| Kelly E Dunham, B Jill Vento. SSRI antidepressants differentially modulate serotonin reuptake and release in Drosophila. Journal of neurochemistry. 2022-06-23. PMID:35736504. |
escitalopram and paroxetine increased serotonin concentrations at all doses, but escitalopram increased reuptake more. |
2022-06-23 |
2023-08-14 |
drosophila_melanogaster |
| Silvia Diviccaro, Silvia Giatti, Lucia Cioffi, Eva Falvo, Rocco Piazza, Donatella Caruso, Roberto C Melcang. Paroxetine effects in adult male rat colon: Focus on gut steroidogenesis and microbiota. Psychoneuroendocrinology. vol 143. 2022-06-14. PMID:35700562. |
paroxetine, a selective serotonin reuptake inhibitor (ssri), is prescribed to treat psychiatric disorders, although an off-label ssri use is also for functional gastrointestinal disorders. |
2022-06-14 |
2023-08-14 |
rat |
| Stefania Chiappini, Rachel Vickers-Smith, Amira Guirguis, John Martin Corkery, Giovanni Martinotti, Fabrizio Schifan. A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases. Pharmaceuticals (Basel, Switzerland). vol 15. issue 5. 2022-05-28. PMID:35631391. |
thus, here we aimed to determine available pharmacovigilance misuse/abuse/dependence/withdrawal signals relating to the selective serotonin reuptake inhibitors (ssri) citalopram, escitalopram, paroxetine, fluoxetine, and sertraline. |
2022-05-28 |
2023-08-13 |
Not clear |
| Dat T N Ngo, Trinh Q Nguyen, Hieu K Huynh, Trang T Nguye. Thermodynamics of selective serotonin reuptake inhibitors partitioning into 1,2-dioleoyl- RSC advances. vol 10. issue 64. 2022-05-06. PMID:35518408. |
in this study, the interaction between two representatives of selective serotonin reuptake inhibitors, including paroxetine and sertraline, and large unilamellar vesicles (luvs) composed of 1,2-dioleoyl- |
2022-05-06 |
2023-08-13 |
Not clear |
| Alexander Lisinski, Fredrik Hieronymus, Staffan Nilsson, Elias Eriksso. Impact of chosen cutoff on response rate differences between selective serotonin reuptake inhibitors and placebo. Translational psychiatry. vol 12. issue 1. 2022-04-15. PMID:35422023. |
using pooled patient-level data sets from trials of three selective serotonin reuptake inhibitors (ssris) (citalopram, paroxetine and sertraline) (n = 7909), and from similar trials of duloxetine (n = 3478), we thus assessed the impact of different cutoffs on response rates. |
2022-04-15 |
2023-08-13 |
human |
| Masaki Kato, Haruhiko Ogata, Hidetoshi Tahara, Akira Shimamoto, Yoshiteru Takekita, Yosuke Koshikawa, Keiichiro Nishida, Shinpei Nonen, Koichiro Higasa, Toshihiko Kinoshit. Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways. International journal of molecular sciences. vol 23. issue 7. 2022-04-12. PMID:35409234. |
this randomized control trial examined mirnas correlated with the early therapeutic effect of selective serotonin reuptake inhibitors (ssris; paroxetine or sertraline) and mirtazapine monotherapy. |
2022-04-12 |
2023-08-13 |
human |
| Miguel Ángel Bruni-Montero, José Manuel Caro-Teller, José Antonio Hernández-Ramos, Cristian Rosas-Espinoza, Dolores Canales-Siguero, José Miguel Ferrari-Piquer. Rivaroxaban and selective serotonin reuptake inhibitors: Bleeding risk resulting from their concomitant use. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. vol 46. issue 1. 2022-04-05. PMID:35379086. |
the combination of selective serotonin reuptake inhibitors with rivaroxaban may result in a dual interaction (pharmacokinetic and pharmacodynamic) depending on the type of selective serotonin reuptake inhibitor employed (cyp3a4-inhibiting vs. non-cyp3a4 inhibiting). the purpose of this study was to use real world data to determine if the type of selective serotonin reuptake inhibitor used plays a role in the risk and severity of bleeding in patients receiving rivaroxaban. method: this was a single-center retrospective longitudinal observational study carried out between january 2016 and february 2020 in patients aged 18 years or older treated concurrently with rivaroxaban (prescribed for treatments) and a selective serotonin reuptake nhibitor. patients were divided into two groups according to the selective serotonin reuptake inhibitor they received, i.e., a cyp3a4 inhibitor (group 1): sertraline, fluoxetine and paroxetine, or a non-cyp3a4 inhibitor (group 2): citalopram and escitalopram. |
2022-04-05 |
2023-08-13 |
Not clear |
| Cinthya Eloisa Chávez-Castillo, Julia Sagahón-Azúa, Karla Itzel Velasco-Gloria, Susanna Edith Medellín-Garibay, Rosa Del Carmen Milán-Segovia, Silvia Romano-Moren. Simultaneous determination of four serotonin selective reuptake inhibitors by an UPLC MS-MS method with clinical application in therapeutic drug monitoring. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. vol 1193. 2022-02-22. PMID:35193100. |
an analytical method of ultra-high performance liquid chromatography coupled to tandem mass spectrometry detection was developed and validated for the simultaneous quantification in plasma of four selective serotonin reuptake inhibitor antidepressants: sertraline, escitalopram, paroxetine, fluoxetine, and its metabolite norfluoxetine. |
2022-02-22 |
2023-08-13 |
Not clear |
| Kuo-Hsuan Chang, Chiung-Mei Chen, Chun-Li Wang, Hui-Tzu Tu, Yu-Tung Huang, Hsiu-Chuan Wu, Chien-Hung Chang, Shang-Hung Chan. Major Bleeding Risk in Patients With Non-valvular Atrial Fibrillation Concurrently Taking Direct Oral Anticoagulants and Antidepressants. Frontiers in aging neuroscience. vol 14. 2022-02-21. PMID:35185526. |
an increased risk of intracerebral hemorrhage (ich) was associated with the combinations of doacs with selective serotonin reuptake inhibitors (ssris, arr: 1.38, 95% ci: 1.08-1.76), particularly in paroxetine (arr: 2.11, 95% ci: 1.17-3.81), and tetracyclic antidepressants (tecas, arr: 1.34, 95% ci: 1.01-1.78). |
2022-02-21 |
2023-08-13 |
Not clear |
| Wisam Al Jumaili, Chintan Trivedi, Timothy Chao, Aaron Kubosumi, Shailesh Jai. The safety and efficacy of Ketamine NMDA receptor blocker as a therapeutic intervention for PTSD review of a randomized clinical trial. Behavioural brain research. 2022-02-19. PMID:35181391. |
the us food drug administration (fda) has approved only two serotonin selective reuptake inhibitors (ssri), sertraline, and paroxetine as pharmacological interventions for ptsd. |
2022-02-19 |
2023-08-13 |
Not clear |
| Peter Tyrer, Helen Tyrer, Min Yan. Relationships between treatments received in the Nottingham Study of Neurotic Disorder over 30 years and personality status. Personality and mental health. 2022-01-04. PMID:34981662. |
over 30 years, patients with dependent and anankastic personality disturbance and cothymia (the general neurotic syndrome) were 2.27 times more likely to receive selective serotonin reuptake inhibitors (ssris) and new antidepressants (95% confidence interval [ci]: 1.22-4.24), particularly paroxetine, and were 1.6 weeks (95% ci: 1.2-2.3) longer on the drug than those without the syndrome. |
2022-01-04 |
2023-08-13 |
Not clear |